AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24951296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (35 mL top-up dose) after the first time trial
Number of subjects: 26
Study 24951296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22329822 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach (community-based victim advocate outreach)
Number of subjects: 236
Study 22329822 — intervention group
Group type: COMPARATOR
Intervention: Referral (criminal justice system-based victim advocate referrals to community-based agencies)
Number of subjects: 236
Study 19744307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 19744307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 0
Study 19744307 — intervention group
Group type: COMPARATOR
Intervention: Endocrine and cytotoxic therapies
Number of subjects: 0
Study 19744307 — intervention group
Group type: COMPARATOR
Intervention: Anthracyclines and taxanes
Number of subjects: 0
Study 17563979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud applications at 38-40 degrees C for AS patients with prevalent spinal lesions
Number of subjects: 71
Study 17563979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud applications at 22-24 degrees C for AS patients with prevalent joint lesions
Number of subjects: 71
Study 17563979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud applications at 38-40 degrees C for AS patients free of inflammation
Number of subjects: 71
Study 17563979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud applications at 22-24 degrees C for patients with reactive arthritis and Reiter's disease
Number of subjects: 71
Study 16244017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative IV ondansetron (4 mg) followed by postoperative ondansetron (8 mg BID for up to 72 h)
Number of subjects: 60
Study 16244017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12107603 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin (0.6 mg day 1, 0.4 mg day 2, then 0.1 mg daily)
Number of subjects: 20
Study 12107603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10460216 — intervention group
Group type: EXPERIMENTAL
Intervention: PvuII polymorphism
Number of subjects: 200
Study 10460216 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 7598300 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐ras gene analysis in patients with pancreatic cancer (group 3)
Number of subjects: 75
Study 7598300 — intervention group
Group type: COMPARATOR
Intervention: K‐ras gene analysis in patients with no pancreatic disease (group 1)
Number of subjects: 75
Study 7598300 — intervention group
Group type: COMPARATOR
Intervention: K‐ras gene analysis in patients with nontumoral pancreatic disease (group 2)
Number of subjects: 75
Study 2121070 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine dressing (CHX dressing)
Number of subjects: 57
Study 2121070 — intervention group
Group type: COMPARATOR
Intervention: Standardized dressing (Control)
Number of subjects: 57
Study 365851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of artificial food colors
Number of subjects: 2
Study 365851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 365851 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge effects
Number of subjects: 2
Study 30929657 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depression (MD)
Number of subjects: 135458
Study 30929657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Consumption (AC) - Quantity
Number of subjects: 135458
Study 30929657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Consumption (AC) - Frequency
Number of subjects: 135458
Study 27741367 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational cigarette with 0.4 mg/g nicotine content
Number of subjects: 839
Study 24993569 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial single-bundle (SB) ACL reconstruction
Number of subjects: 47
Study 24993569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic SB ACL reconstruction
Number of subjects: 47
Study 24993569 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 47
Study 24993569 — intervention group
Group type: EXPERIMENTAL
Intervention: KT-1000 knee laxity measurements
Number of subjects: 47
Study 24993569 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS and IKDC subjective outcome scores
Number of subjects: 47
Study 24113764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet‐based maintenance treatment (TIMT)
Number of subjects: 400
Study 24113764 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control condition
Number of subjects: 400
Study 21835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 79
Study 21835552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 21835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge behavioral treatment
Number of subjects: 79
Study 21835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-hospitalization
Number of subjects: 79
Study 19271826 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida's Family Transition Program (FTP)
Number of subjects: 0
Study 19271826 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparable group of single-mother welfare-recipient families)
Number of subjects: 0
Study 17676252 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 3870
Study 17676252 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 3870
Study 17676252 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 3870
Study 15161945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 107
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-behavioral curricula in schools, peer leadership activities, parental involvement and education, community-wide activities
Number of subjects: 0
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy to refuse offers of alcohol among those who did not use alcohol at baseline
Number of subjects: 0
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influence to use, including normative estimates
Number of subjects: 0
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional meanings of alcohol use
Number of subjects: 0
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes and behaviors associated with alcohol and drug problems like stimulus seeking, rule violations and bad judgement
Number of subjects: 0
Study 11252284 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child alcohol-related communication around alcohol use
Number of subjects: 0
Study 9552137 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAGF: 0.3 wt% docosahexaenoic acid and 0.5 wt% gamma‐linolenic acid
Number of subjects: 37
Study 9552137 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAF: 0.3 wt% docosahexaenoic acid
Number of subjects: 37
Study 9552137 — intervention group
Group type: COMPARATOR
Intervention: STF: standard formula without long‐chain polyunsaturated fatty acids
Number of subjects: 37
Study 9552137 — intervention group
Group type: EXPERIMENTAL
Intervention: All formula-fed infants
Number of subjects: 37
Study 8109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5 mg bupivacaine + 22.2 +/- 4.6 mL epidural lidocaine
Number of subjects: 80
Study 8109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 5 mg bupivacaine + 10.1 +/- 2.0 mL epidural lidocaine
Number of subjects: 80
Study 8109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 7.5 mg bupivacaine
Number of subjects: 80
Study 8109762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg bupivacaine
Number of subjects: 80
Study 2842144 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.001, 0.003, 0.007 or 0.014 mg kg-1)
Number of subjects: 110
Study 2842144 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (3.0 mg)
Number of subjects: 110
Study 2842144 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 110
Study 2842144 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg)
Number of subjects: 110
Study 2842144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31016502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) or myocardial perfusion scintigraphy (MPS)
Number of subjects: 292
Study 28174327 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based thrombolysis
Number of subjects: 1005
Study 28174327 — intervention group
Group type: COMPARATOR
Intervention: Daytime unwitnessed stroke
Number of subjects: 1005
Study 26261386 — intervention group
Group type: EXPERIMENTAL
Intervention: fluconazole 150 mg 1x weekly
Number of subjects: 133
Study 26261386 — intervention group
Group type: EXPERIMENTAL
Intervention: itraconazole continual therapy
Number of subjects: 133
Study 26261386 — intervention group
Group type: EXPERIMENTAL
Intervention: itraconazole pulse therapy
Number of subjects: 133
Study 26261386 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine 250 mg/d
Number of subjects: 133
Study 26261386 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine + ciclopirox 8% lacquer
Number of subjects: 133
Study 23503447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (n = 98)
Number of subjects: 275
Study 23503447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted fosamprenavir (n = 69)
Number of subjects: 275
Study 23503447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted saquinavir (n = 99)
Number of subjects: 275
Study 21146259 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality training for nurses
Number of subjects: 75
Study 19555446 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (0.8 g/dL of scGOS and lcFOS, ratio 9:1)
Number of subjects: 76
Study 19555446 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrines (placebo)
Number of subjects: 76
Study 16905065 — intervention group
Group type: COMPARATOR
Intervention: RME-only
Number of subjects: 66
Study 16905065 — intervention group
Group type: COMPARATOR
Intervention: RME-Sz
Number of subjects: 66
Study 14716693 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (2.5-10 mg/day)
Number of subjects: 16
Study 14716693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11729740 — intervention group
Group type: EXPERIMENTAL
Intervention: mf-ERG
Number of subjects: 24
Study 11729740 — intervention group
Group type: COMPARATOR
Intervention: Full-field ERG
Number of subjects: 24
Study 9709137 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope with modified cricoid pressure
Number of subjects: 100
Study 9709137 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope without modified cricoid pressure
Number of subjects: 100
Study 8019022 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 0
Study 8019022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2660958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol-240 (MP-238)
Number of subjects: 50
Study 2660958 — intervention group
Group type: COMPARATOR
Intervention: Iothalamate-202 (Conray 43)
Number of subjects: 50
Study 31077311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/gemcitabine chemotherapy
Number of subjects: 109
Study 27432587 — intervention group
Group type: COMPARATOR
Intervention: Standard ablation system
Number of subjects: 0
Study 27432587 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ablation system
Number of subjects: 0
Study 25948767 — intervention group
Group type: EXPERIMENTAL
Intervention: High PUFA dietary supplementation
Number of subjects: 0
Study 25948767 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplementation without PUFA)
Number of subjects: 0
Study 23183442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine (loading dose of 20 mg quinine dihydrochloride/kg)
Number of subjects: 75
Study 23183442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular quinine
Number of subjects: 75
Study 21451166 — intervention group
Group type: EXPERIMENTAL
Intervention: New upper bedding duck feather pillow and quilt with a mite-occlusive mattress cover
Number of subjects: 197
Study 21451166 — intervention group
Group type: COMPARATOR
Intervention: Standard care with a mite-occlusive mattress cover
Number of subjects: 197
Study 19116400 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent film dressing
Number of subjects: 100
Study 19116400 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive bandage
Number of subjects: 100
Study 19116400 — intervention group
Group type: COMPARATOR
Intervention: Pressure dressing
Number of subjects: 100
Study 16448867 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa preparation 1
Number of subjects: 24
Study 16448867 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa preparation 2
Number of subjects: 24
Study 14982261 — intervention group
Group type: EXPERIMENTAL
Intervention: 56-French Pilling dilators
Number of subjects: 30
Study 14982261 — intervention group
Group type: COMPARATOR
Intervention: 40-French Pilling dilators (Control)
Number of subjects: 30
Study 14982261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (56-French and 40-French dilators)
Number of subjects: 30
Study 12740337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 660
Study 12740337 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 660
Study 12740337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 10638351 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback treatment
Number of subjects: 0
Study 10638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Age matched reference normative QEEG database
Number of subjects: 0
Study 10638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind research study
Number of subjects: 0
Study 8929256 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg o.d.
Number of subjects: 147
Study 8929256 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d.
Number of subjects: 147
Study 8929256 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil + pravastatin (same doses)
Number of subjects: 147
Study 8929256 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study 1404679 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin twice daily
Number of subjects: 444
Study 1404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin or low-dose aspirin (80 to 325 mg daily)
Number of subjects: 444
Study 1404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin
Number of subjects: 444
Study 1404679 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall aspirin usage
Number of subjects: 444
Study 3981950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMW heparin) at 50% of the normal unfractionated heparin (UF heparin) dose
Number of subjects: 49
Study 3981950 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 49
Study 3981950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMW heparin)
Number of subjects: 49
Study 3981950 — intervention group
Group type: COMPARATOR
Intervention: UF heparin and LMW heparin
Number of subjects: 49
Study 3286383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 11.1 mg/kg per day (group A)
Number of subjects: 33
Study 3286383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursomenth (UDCA/menthol mixture: 4.75 mg/kg per day each) (group B)
Number of subjects: 33
Study 30916194 — intervention group
Group type: EXPERIMENTAL
Intervention: β1 specific beta-blockers + alpha 1-blocker
Number of subjects: 18
Study 30916194 — intervention group
Group type: COMPARATOR
Intervention: β1 non-specific beta-blockers
Number of subjects: 18
Study 27618578 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n=7)
Number of subjects: 27
Study 27618578 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention, waiting list control group (n=14)
Number of subjects: 27
Study 27618578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled intervention data (n=21)
Number of subjects: 27
Study 25168020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-MP-General LCD monitor
Number of subjects: 100
Study 25168020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-MP-Medical LCD monitor
Number of subjects: 100
Study 25168020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-MP-Medical LCD monitor
Number of subjects: 100
Study 23499394 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot bath containing green tea polyphenols (GTP)
Number of subjects: 94
Study 23499394 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (lukewarm water foot bath)
Number of subjects: 94
Study 21545249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled montelukast 1 mg plus inhaled mometasone 220 μg
Number of subjects: 134
Study 21545249 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus inhaled mometasone 220 μg
Number of subjects: 134
Study 19789401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of bone marrow-derived mononuclear cells (BMC) within 7 days after successful reperfusion therapy for AMI.
Number of subjects: 187
Study 19789401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 187
Study 16730616 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/d for 12 weeks
Number of subjects: 75
Study 16730616 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/d for 12 weeks with aggressive toenail debridement
Number of subjects: 75
Study 16730616 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 15127196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pulmonary infection score (CPIS) > 6 on day 3
Number of subjects: 201
Study 15127196 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy-based diagnosis of VAP
Number of subjects: 201
Study 15127196 — intervention group
Group type: EXPERIMENTAL
Intervention: CPIS > 6 on day 3
Number of subjects: 201
Study 11116283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedotozine
Number of subjects: 0
Study 9565786 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash lamp‐pumped pulsed dye laser (FPDL)
Number of subjects: 40
Study 9565786 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 40
Study 7840428 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon FEP catheter (Cathlon Critikon)
Number of subjects: 350
Study 7840428 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane Vialon catheter (Insyte Becton‐Dickinson)
Number of subjects: 350
Study 7840428 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel needles
Number of subjects: 350
Study 2826526 — intervention group
Group type: COMPARATOR
Intervention: Insulin (0.1 U/kg, iv) followed by placebo
Number of subjects: 16
Study 2826526 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.1 U/kg, iv) followed by oral clonidine (0.150 mg)
Number of subjects: 16
Study 2826526 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine (0.150 mg) followed by iv placebo
Number of subjects: 16
Study 2826526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.150 mg) followed by iv insulin (0.1 U/kg)
Number of subjects: 16
Study 30899972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (tidal volume 7ml/kg ideal body weight, PEEP ideal body weight/10), n=535
Number of subjects: 1021
Study 30899972 — intervention group
Group type: COMPARATOR
Intervention: Apnea (manual/spontaneous, APL valve 0mbar), n=486
Number of subjects: 1021
Study 28422533 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TD)
Number of subjects: 59
Study 28422533 — intervention group
Group type: COMPARATOR
Intervention: Pyramid Resistance Training (PR)
Number of subjects: 59
Study 28422533 — intervention group
Group type: EXPERIMENTAL
Intervention: Control Group (CG)
Number of subjects: 59
Study 26602298 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant feeding intervention delivered by 9 village health workers
Number of subjects: 19
Study 24325771 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education counseling
Number of subjects: 755
Study 24325771 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (regardless of counseling type)
Number of subjects: 755
Study 22111770 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 111)
Number of subjects: 336
Study 22111770 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 115)
Number of subjects: 336
Study 22111770 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 110)
Number of subjects: 336
Study 19271165 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinyue Capsule (XYC) plus Composite Salvia Tablet (CST)
Number of subjects: 75
Study 19271165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16971855 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% human albumin
Number of subjects: 691
Study 16971855 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 691
Study 16971855 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% human albumin with >3 L of fluids in the first 24 hrs
Number of subjects: 691
Study 16971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (amount)
Number of subjects: 691
Study 15563344 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) three times daily for 4 consecutive weeks
Number of subjects: 96
Study 15563344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 96